On this World Arthritis Day, patients with inflammatory diseases have increasing treatment options as biosimilars gain regulatory approval and become more widely available for use. New clinical data also help support the efficacy and safety of these therapies.
On this World Arthritis Day, patients with inflammatory diseases have increasing treatment options as biosimilars gain regulatory approval and become more widely available for use. New clinical data also help support the efficacy and safety of these therapies.
Biologic treatments are known to be effective in the treatment of inflammatory diseases, including rheumatoid arthritis (RA), and new data add to the body of evidence showing that biosimilar etanercept has comparable efficacy to the originator drug. A recent study of Samsung Bioepis’ SB4 (which is approved in the Republic of Korea, the European Union, Australia, and Canada) observed no difference in radiographic progression of RA in patients receiving SB4 and patients receiving the originator etanercept, at 52 weeks of treatment.
While clinical efficacy of a biologic therapy is critical, adherence to the treatment regimen is also important for good outcomes. A recent study found that enrollment in patient support programs was associated with greater adherence to adalimumab (Humira) therapy, as well as with reduced healthcare costs. These programs assist patients, including those with RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), with drug costs, in addition to providing injection training and nursing support. The study found that patients enrolled in these programs had a 14% higher rate of treatment adherence than control patients who did not utilize these programs.
Unfortunately, despite treatment adherence, some patients do not achieve an adequate response. A recent paper recommends switching patients with PA who are non-responders to a different biologic therapy. The paper’s authors investigated 13 studies in which patients with PA were switched after failing to respond or no longer responding to a biologic, and found that switching to a different drug could be both safe and effective, especially when switching to a biologic with a different method of action.
Newer drugs, including IL-6 inhibitors like tocilizumab (Acterma), also present patients with good therapeutic options; a new study comparing the clinical effectiveness of anti—tumor necrosis factor (TNF) agents such as etanercept, adalimumab, certolizumab pegol, infliximab, and golimumab found that tocilizumab outperformed anti-TNF agents in both effectiveness and drug survival. However, excitement about IL-6 inhibitors has been tempered by concerns about safety in at least 1 case: the FDA recently issued a complete response letter to Janssen Biotech for the company’s proposed IL-6 inhibitor, sirukumab. The drug was associated with a number of patient deaths during its clinical program.
Despite advances in drug development and approval, patients continue to face challenges in navigating access to the most appropriate treatments for their arthritis; many health plans use “step therapy,” (sometimes called “fail-first therapy”) a policy that requires doctors to prescribe older, less expensive drugs first in an effort to save on costs. Only after a patient has failed to respond to such therapies can a physician prescribe a newer, more expensive drug, such as a biologic or a biosimilar. In diseases like RA, delays in access to better treatment can lead to pain, loss of function, and higher healthcare costs.
While step therapy may force patients to receive a number of drugs before they reach higher-cost treatments like biologics, physicians are concerned that other payer policies could also have an impact on what drugs they prescribe their patients. Because formulary decisions can restrict which treatment a provider can prescribe, some clinicians are voicing concerns that patients may have to switch treatments among non-interchangeable biologics and biosimilars.
In a recent Peer Exchange panel discussion by The Center for Biosimilars®, Marcus Snow, MD, of the University of Nebraska Medical Center, raised questions about multiple switches among products, saying, “Does your body react to that long term? Do you lose efficacy? Does it increase your immunogenicity, which basically means that you have more drug-to-drug antibodies because you switched from product A to product B and maybe then to product C then back to product B, depending on how the winds blow with the formulary? That’s something that, as rheumatologists, we are very concerned about. And it’s something that we are trying to help regulate with the FDA.”
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.